Ireland· IE-PA-EU/1/24/1798/001
Lytenava 25 mg/mL solution for injection
A bevacizumab product containing bevacizumab, registered in Ireland by Outlook Therapeutics NL B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Bevacizumab is registered in 9 of 19 countries.
Countries holding a registration under ATC S01LA08 (bevacizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 5 of them publish a price we can compare per daily dose
Bevacizumab · ATC S01LA08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- Bevacizumab
- Manufacturer
- Outlook Therapeutics NL B.V.
- Country
- Ireland (IE)
- ATC code
- S01LA08
- ATC class
- Bevacizumab
- Defined daily dose
- 0.036 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1798/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bevacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLytenava 25 mg/mlOutlook Therapeutics NL
- CzechiaLYTENAVAOutlook Therapeutics NL B.V., Amsterdam
- IcelandLytenavaOutlook Therapeutics NL B.V.
- NetherlandsLytenava 25 mg/ml oplossing voor injectieOutlook Therapeutics NL B.V.
- PolandLytenavaOutlook Therapeutics Limited
- SwedenLytenava 25 mg/ml Injektionsvätska, lösningOutlook Therapeutics NL B.V.
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
- United StatesALYMSYSAmneal Pharmaceuticals LLC
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec13e41a-a17e-4cb4-93b6-3b929374d274 GET /v1/drugs/ec13e41a-a17e-4cb4-93b6-3b929374d274?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Intravitreal use"
],
"source": "hpra",
"atc_all": [
"S01LA08"
],
"strength": null,
"pa_number": "EU/1/24/1798/001",
"substances": [
"Bevacizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "27/05/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about bevacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.